AMG 458 / Amgen - LARVOL DELTA

Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. (PubMed, Anticancer Res) - "PHA665752 combined with MTX synergistically inhibits OS cell growth via dual suppression of c-Met signaling (PI3K/AKT, MAPK/ERK). and MTX-mediated cytotoxicity, highlighting the potential of co-targeting overlapping pathways to enhance OS treatment efficacy."

Heterogeneity • Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NOS1

Discovering novel therapies in the treatment of osteosarcoma (AACR 2022) - "These drugs are: BRL-15572 (dihydrochloride), PH-797804, Apalutamide (ARN-509), AMG-458, Ipatasertib (GDC-0068), Mifepristone, Prucalopride, VU 0361737, Olopatadine HCl, and AZ 3146. The in vitro test results are promising and provide the groundwork to proceed with in vivo testing on orthotopic xenograft models. These models will be used for drug testing of the narrowed drug agents, with tumor growth inhibition and survival time of the drug treatment group monitored against a control group without drug exposure. Results from in vivo testing will be proposed for future clinical trials for treating pediatric osteosarcoma."

Lung Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor